Colorectal Cancer study: DSP107 + Atezolizumab vs Fruquintinib
Official title A Study to Test DSP107 in Combination With Atezolizumab in Comparison With Fruquintinib as a New Treatment for Colorectal Cancer.
ClinicalTrials.gov ID: NCT07235293
What this study is testing
What is DSP107 + Atezolizumab?
This is an investigational combination of two medicines being studied as a potential treatment for advanced colorectal cancer. Atezolizumab is designed to help the immune system recognize and attack cancer cells, while DSP107 is a new medicine being studied for its effects on cancer growth.
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The study compares how well the new combination works and how safe it is compared to the existing drug fruquintinib. It also looks at how the body handles the medicines.
- Who it's for
- Adults with advanced colorectal cancer that is microsatellite stable (MSS).
- What's involved
- Participants will be randomly given either the DSP107 plus atezolizumab combo or fruquintinib. They will have regular visits where doctors check cancer response, safety, and drug levels. No other treatments are mentioned.
- Time commitment
- The study lasts until the treatment period ends, with scheduled visits for monitoring. The exact length is not specified in the source.
- Phase 2: a mid-size study of how well it works
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Are ≥ 18 years of age with a life expectancy of \> 3 months.
- Participants with histologically confirmed, inoperable, MSS and/or pMMR CRC which has progressed to, or is intolerant to, specified therapies (and...
- Measurable disease per RECIST v1.1.
You likely can't join if
- Central nervous system (CNS) metastases unless stable 2 months post definitive therapy with steroids.
- Unresolved AEs of Grade 2 or higher from prior anticancer therapy.
- Past or current history of autoimmune disease or immune deficiency.
- History of other malignancy within 3 years of first study treatment cycle.
- Current or recent treatment with certain therapies including specified anticancer treatments, modulators of CYP3A4 and immunomodulating therapies...
- Known allergy or hypersensitivity to any of the test compounds, materials, or contraindication to test product.
See the full eligibility criteria
- Are ≥ 18 years of age with a life expectancy of \> 3 months.
- Participants with histologically confirmed, inoperable, MSS and/or pMMR CRC which has progressed to, or is intolerant to, specified therapies (and has received prior treatment with no more than 3 lines of therapy).
- Measurable disease per RECIST v1.1.
- Central nervous system (CNS) metastases unless stable 2 months post definitive therapy with steroids.
- Unresolved AEs of Grade 2 or higher from prior anticancer therapy.
- Past or current history of autoimmune disease or immune deficiency.
- History of other malignancy within 3 years of first study treatment cycle.
- Current or recent treatment with certain therapies including specified anticancer treatments, modulators of CYP3A4 and immunomodulating therapies (prior treatment with CPIs is not exclusory).
- Known allergy or hypersensitivity to any of the test compounds, materials, or contraindication to test product.
- Clinically significant abnormal laboratory safety tests.
The study team makes the final eligibility decision.
Where it is enrolling
- Aurora, Colorado, United States
- Highlands Ranch, Colorado, United States
- Florida City, Florida, United States
- Durham, North Carolina, United States
- Pittsburgh, Pennsylvania, United States
- Texas City, Texas, United States
- Woodville, Adelaide, Australia
- Camperdown, New South Wales, Australia
- Port Macquarie, New South Wales, Australia
- Westmead, New South Wales, Australia
- South Brisbane, Queensland, Australia
- Bedford Park, South Australia, Australia
- Clayton, Victoria, Australia
- Footscray, Victoria, Australia
- Heidelberg, Victoria, Australia
- Melbourne, Victoria, Australia
- Saint Albans, Victoria, Australia
- Nedlands, Western Australia, Australia
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Aurora, Colorado, United States; Highlands Ranch, Colorado, United States; Florida City, Florida, United States; Durham, North Carolina, United States; Pittsburgh, Pennsylvania, United States; Texas City, Texas, United States and 12 more locations. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.